miR‑95 promotes osteosarcoma growth by targeting SCNN1A

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) is a prevalent bone cancer in young individuals with a poor long-term prognosis.
• MicroRNAs (miRNAs) are implicated in cancer development, but the role of miR-95 in OS remains uncharacterized.
• Understanding novel molecular mechanisms is crucial for improving OS treatment strategies.

Purpose of the Study:

• To investigate the role and mechanism of miR-95 in osteosarcoma (OS) progression.
• To determine if miR-95 could serve as a potential diagnostic biomarker for OS.

Main Methods:

• Analysis of publicly available Gene Expression Omnibus (GEO) data for miR-95 expression in OS.
• In vitro studies using OS cell lines with miR-95 inhibitors (EdU, TUNEL, flow cytometry).
• In vivo studies using a mouse xenograft model with miR-95 antagomirs and dual luciferase reporter assays to identify miR-95 targets.

Main Results:

• Abnormal miR-95 expression was detected in osteosarcoma tissues via GEO database analysis.
• miR-95 inhibition significantly decreased OS cell proliferation and induced apoptosis in vitro.
• miR-95 was found to target the sodium channel epithelial 1α subunit (SCNN1A), regulating cell cycle and apoptosis.
• In vivo, miR-95 antagomirs suppressed tumor growth in a mouse model.

Conclusions:

• miR-95 promotes osteosarcoma growth both in vitro and in vivo.
• The mechanism involves miR-95 targeting of SCNN1A, affecting cell cycle and apoptosis.
• miR-95 represents a potential diagnostic target for osteosarcoma.